Chondromalacia Patella: Can Stem Cells Help?. Chondromalacia patella explained: pain behind the kneecap, grades of cartilage softening, strength-based care, injections and when stem cell therapy is considered.
Chondromalacia patella is softening of the cartilage behind the kneecap. Strength work helps most people, and stem cell therapy may be considered for ongoing pain with early to moderate cartilage changes.
A dull ache behind or around the kneecap, worse on stairs or after sitting through a film, is one of the most common knee complaints in adults. When a scan shows the cartilage under the kneecap has softened or roughened, the name for it is chondromalacia patella.
It often affects runners, people who squat a lot and adults over 40. Because cartilage has a poor blood supply, it does not repair itself easily. That is why many people with this condition begin asking whether stem cell therapy could help.
The kneecap glides in a groove at the end of the thigh bone. When it tracks slightly off-centre, or carries more load than it can handle, the cartilage underneath wears unevenly.
| Grade | What the Cartilage Looks Like | What It Usually Means | |---|---|---| | Grade 1 | Softened but smooth | Early change, often very responsive to strength work | | Grade 2 | Small surface cracks | Mild wear, usually managed without surgery | | Grade 3 | Deeper cracks and fraying | Moderate wear, symptoms may persist | | Grade 4 | Cartilage worn down to bone | Advanced change, close to patellofemoral arthritis |
An MRI is the best way to see these grades. A plain X-ray mainly shows kneecap position and later arthritis.
Stem cell therapy, often using MSC therapy, is discussed for people whose pain continues despite months of good rehabilitation. MSCs release signals that may calm inflammation and support the joint environment around damaged cartilage.
It is most often considered when:
It is less suitable when the kneecap is badly misaligned, when there is a loose fragment of cartilage, or when the joint is fully worn. Cell therapy does not reshape the kneecap groove, so tracking problems still need exercise or surgical correction. Read more on stem cell therapy for knee cartilage defects.
| Option | How It Helps | Best Suited For | |---|---|---| | Hip and thigh strengthening | Improves kneecap control and reduces pressure | All grades, first step for everyone | | Taping or bracing | Supports kneecap tracking during activity | Flares and return to sport | | Activity changes | Reduces deep squats, stairs and jumping for a while | Painful phases | | Hyaluronic or steroid injections | Short-term relief of irritation | Flares that block rehabilitation | | Stem cell therapy (MSC therapy) | Supports the joint environment and calms inflammation | Grade 2 to 3 with ongoing pain despite rehab | | Surgery | Smooths cartilage or realigns the kneecap | Loose fragments or major tracking problems |
Aim for exercises that feel comfortable or mildly achy, with no worsening the next morning.
Early softening often settles with strength work and load changes, although the cartilage itself does not fully regrow.
Not always. Many people keep running at a lower volume while they build hip and thigh strength.
It is not expected to rebuild cartilage fully. The aim is to support the joint and ease inflammation and pain.
An MRI read by a specialist shows the grade. Your symptoms alone cannot confirm it.
No. Most people improve without surgery, which is kept for loose fragments or major tracking problems.
Chondromalacia patella is softening of the cartilage behind the kneecap, usually linked to weak hip and thigh muscles, poor kneecap tracking or overload, and it shows up as stair pain, grinding and aching after sitting. Strength work and load changes help most people, while stem cell therapy may be considered for grade 2 to 3 changes with pain that continues despite good rehabilitation, and surgery is kept for loose fragments or major tracking problems.
1. Patellofemoral pain syndrome - OrthoInfo, AAOS 2. Mesenchymal stromal cells for patellofemoral cartilage - Google Scholar 3. Important patient and consumer information about regenerative medicine therapies - FDA